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Abstract
Purpose Spondyloenchondrodysplasia is a rare immuno-
osseous dysplasia caused by biallelic mutations in ACP5.
We aimed to provide a survey of the skeletal, neurological
and immune manifestations of this disease in a cohort of mo-
lecularly confirmed cases.
Methods We compiled clinical, genetic and serological data
from a total of 26 patients from 18 pedigrees, all with biallelic
ACP5 mutations.
Results We observed a variability in skeletal, neurological and
immune phenotypes, which was sometimes marked even be-
tween affected siblings. In total, 22 of 26 patients manifested
autoimmune disease, most frequently autoimmune thrombo-
cytopenia and systemic lupus erythematosus. Four patients
were considered to demonstrate no clinical autoimmune dis-
ease, although two were positive for autoantibodies. In the
majority of patients tested we detected upregulated expression
of interferon-stimulated genes (ISGs), in keeping with the
* Tracy A. Briggs
tracy.briggs@manchester.ac.uk
1 Manchester Centre for Genomic Medicine, Institute of Human
Development, Faculty of Medical and Human Sciences, University
of Manchester, Manchester, UK
2 St Mary’s Hospital, Central Manchester University Hospitals NHS
Foundation Trust, Manchester Academic Health Science Centre,
Manchester, UK
3 Department of Rheumatology, The LadyCilento Children’s Hospital,
Brisbane, Australia
4 Department of Clinical Genetics, The Children’s Hospital at
Westmead, Sydney, Australia
5 Discipline of Paedatrics and Child Health, The University of Sydney,
Sydney, Australia
6 Dermatology Department, Pitie-Salpetriere Hospital, Paris, France
7 Creighton University, 2500 California Plaza, NE 68178,
Omaha, USA
8 Pediatric Nephrology Department, Robert Debré University Hospital
– APHP, 48 boulevard Sérurier, 75019 Paris, France
9 Goztepe Educational and Research Hospital Pediatric Endocrinology
Clinic, Istanbul, Türkiye
10 Pediatric Imaging Unit, Cliniques universitaires Saint-Luc,
Université catholique de Louvain, Brussels, Belgium
11 Neuroscience Department, The Lady Cilento Children’s Hospital,
Brisbane, Australia
12 School of Medicine, Griffith University, Gold Coast, Australia
13 Pediatric Rheumatology, Department of Pediatrics, University
Hospitals Leuven, B-3000 Leuven, Belgium
14 Danek Gertner Institute of Human Genetics, Chaim Sheba Medical
Center, Tel Aviv, Israel
15 Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
16 Amasya University Medical Faculty, Department of Pediatric
Endocrinology, Istanbul, Türkiye
17 Department of Pediatric Hematology and Oncology, Trousseau
Hospital, Assistance Publique–Hôpitaux de Paris (APHP),
Paris, France
18 Clinic for Pediatrics I, Inherited Metabolic Disorders, Medical
University of Innsbruck, Anichstr. 35, A-6020 Innsbruck, Austria
19 J. J. M. Medical College, Davangere, Karnataka 577004, India
J Clin Immunol (2016) 36:220–234
DOI 10.1007/s10875-016-0252-y
autoimmune phenotype and the likely immune-regulatory
function of the deficient protein tartrate resistant acid phos-
phatase (TRAP). Two mutation positive patients did not dem-
onstrate an upregulation of ISGs, including one patient with
significant autoimmune disease controlled by immunosup-
pressive therapy.
Conclusions Our data expand the known phenotype of
SPENCD. We propose that the OMIM differentiation between
spondyloenchondrodysplasia and spondyloenchondrodysplasia
with immune dysregulation is no longer appropriate, since the
molecular evidence that we provide suggests that these pheno-
types represent a continuum of the same disorder. In addition,
the absence of an interferon signature following immunomod-
ulatory treatments in a patient with significant autoimmune dis-
ease may indicate a therapeutic response important for the im-
mune manifestations of spondyloenchondrodysplasia.
Keywords Spondyloenchondrodysplasia . SPENCD/
SPENCDI .ACP5 . tartrate-resistant acid phosphatase
(TRAP) . type I interferon . interferon signature
Introduction
Spondyloenchondrodysplasia (SPENCD) (OMIM: 271,550)
is a skeletal dysplasia, characterised by radiolucent
metaphyseal and vertebral lesions [1]. Enchondromas pre-
dominantly develop within long bones, but may also occur
in other areas of endochondral growth [2, 3]. The severity of
the lesions varies, but slow progression during childhood is
most frequently observed, resulting in significant short stature
[2]. The first extra-osseous manifestations reported in
SPENCD were of neurological dysfunction, including devel-
opmental delay and spasticity, which may be associated with
intracranial calcification [2–5]. It was subsequently
recognised that autoimmune disease was also a prominent
feature [2, 3, 6].
SPENCD is caused by biallelic mutations in ACP5,
encoding tartrate-resistant acid phosphatase (TRAP) [7, 8].
Affected individuals displayed an absence of TRAP serum
expression and, in keeping with autoimmune manifestations,
increased levels of serum interferon-alpha (IFNα) and an up-
regulation of interferon-stimulated genes (ISGs) (an interferon
signature) [7]. An interferon signature is also recognised in
SLE [9] and in monogenic disease in association with muta-
tions in TMEM173 [10] and ISG15 [11] and any of the phe-
notypes recognised with mutations in TREX1, RNASEH2A/B/
C, SAMHD1, ADAR1 and IFIH1 - including the monogenic
encephalopathy Aicardi-Goutières syndrome (AGS), which
can show significant overlap with SPENCD [12, 13].
Interestingly, since the description of causative ACP5 mu-
tations [7, 8] the disorder has been designated under two sep-
arate Online Mendelian Inheritance in Man (OMIM) entries,
namely SPENCD (271,550) and SPENCD with immune dys-
regulation (SPENCDI) (607,944). SPENCD is described as a
skeletal and neurological disorder of unknown aetiology.
Whilst SPENCDI, refers to patients with an immune pheno-
type, in addition to the typical skeletal and neurological fea-
tures, and is attributed to ACP5 mutations.
Here, we present data from 26 patients with biallelic ACP5
mutations conforming to both the SPENCD and SPENCDI
phenotypes, leading us to propose that these phenotypes




Twenty-six subjects with a clinical diagnosis of SPENCD
(based on bone, brain and/or immune features, i.e. per current
OMIM classification of SPENCD or SPENCDI) from 18 in-
dependent pedigrees were recruited through collaborating
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Mutation Analysis
All coding exons of ACP5 were sequenced as described pre-
viously [7]. Variant pathogenicity was analysed using Alumut
and minor allele frequency was assessed using the National
Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project (ESP) database.
Interferon Analysis
Type I interferon activity was determined using a cytopathic
reduction assay [7]. As previously described [12], qPCR was
performed on cDNA derived from whole blood and the me-
dian fold change of six interferon-simulated genes was com-
pared with the median of the combined controls, to create an
interferon score for each patient. Scores higher than the mean




All 26 patients with a clinical diagnosis of SPENCD/
SPENCDI harboured homozygous or compound hetero-
zygous ACP5 mutations (Table 1, Fig. 1). These data
confirm the autosomal recessive nature of the disorder
and suggest that it is not a genetically heterogeneous
condition. The observation that 15 out of 18 families
have a history of consanguinity is in keeping with the
low minor allele frequency of pathogenic heterozygous
variants in control populations. Seventeen different mu-
tations distributed throughout the gene were identified
(Fig. 1). Four mutations were observed in more than
one pedigree, whilst the remainder were private to indi-
vidual pedigrees.
Clinical Data
The most frequent reason for first seeking medical attention,
in a total of 13 patients, was due to symptoms of immune
disease, particularly autoimmune thrombocytopenia (AITP),
which prompted presentation in five patients (Table 1).
Skeletal manifestations, with short stature or leg pain/bowing,
were the reason for initial presentation in 12 patients, whilst in
six a neurological phenotype was manifest. In five individ-
uals, complaints in more than one system prompted presenta-
tion. The age at which features first necessitated medical con-
sultation varied from birth to 15 years.
The varied nature and severity of the disease continued
throughout the disease course. For example, Patient 18 pre-
sented at two years of age with short stature. After which, she
did not develop any additional features – so that at 36 years of
age she was of normal intellect, in full time employment and
gave birth to her first child. In contrast, Patient 1 presented at
three years of age with seizures, and suffered a severe, pro-
gressive deterioration with skeletal, neurological and multi-
organ autoimmune disease [3]. Marked variation was evident
between the seven sib-pairs within the cohort, Patient 2 and 3
for example are non-identical twins and at 13 years of age
Patient 2 was 5.5 SD below the mean for height, due to spas-
ticity was classified as level 3 on the Gross Motor
Classification System and manifested hypothyroidism and
SLE with Class IV nephritis. In contrast Patient 3 was 2.5
SD below the mean for height, had no neurological manifes-
tations and was diagnosed with eczema, AITP and proteinuria
and did not fulfil lupus diagnostic criteria.
Skeletal Manifestations
Until recently the diagnosis of SPENCD was made based on
the presence of characteristic radiolucent metaphyseal and
vertebral lesions (Fig. 2). Evenwith molecular testing, skeletal
findings remain an important diagnostic clue. Thus, although
short stature did not always lead to medical referral (perhaps
because autoimmune or neurological features were more
problematic), in all patients where assessment was undertak-
en, skeletal manifestations were evident on radiographs, with
features of both platyspondyly and metaphyseal dysplasia in
23, and either platyspondyly or metaphyseal dysplasia in a
further two (Table 2). We tested over 30 patients with a neu-
rological and/or autoimmune phenotype, including AITP,
SLE, intracranial calcification with seizures or spasticity, but
without typical skeletal radiological changes, and did not
identify biallelic ACP5 mutations.
The skeletal phenotype is variable, with stature fromwithin
the normal range to 6.5 SD below the mean. Exacerbation of
the degree of short stature over time was evident; for example,
Patient 22 progressed from 3 to 5.5 SD below the mean be-
tween 15 and 35 years of age. Short stature was due to short
trunk and/or short limbs depending upon the relative degree of
spinal and/or long bone dysplasia. A number of patients also
manifested specific skeletal deformities, including short distal
phalanges (Patient 4 and 5), kyphosis and pectus carinatum
(Patient 22) [4]. Bone mineral density was normal in Patient 2
and 19, whilst it was increased in Patient 4 and 5 (above
superior percentile for age) and Patient 10 (1.5 SD above
mean), although there was no evidence of localized
osteopetrosis. Patient 17 demonstrated growth hormone
(GH) deficiency and height improved with GH treatment.
However, we are not aware of GH deficiency in other patients









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Clin Immunol (2016) 36:220–234 223
and indeed GH supplementation has been tried in at least one
other patient without any effect on growth.
Neurological Manifestations
Neurological features are frequent in ACP5-associated
disease. We observed spasticity in eleven patients
(44 %), and developmental delay in seven patients
(28 %) (Table 2). Delay was typically of mild to moderate
severity, except in Patient 11, who presented at age two
years with hypothyroidism and severe delay. Additional
neurological features included ataxia, seizures, psychosis
and painful multifocal neuropathy.
Intracranial calcification was demonstrated on cranial CT
imaging in nine out of the thirteen patients assessed (62 %),
variably involving the basal ganglia, pons, dentate nuclei of
the cerebellum and white-grey matter junction. Figure 3 dem-
onstrates the intracerebral calcification observed in Patient
21, associated with a history of spasticity, developmental de-
lay and autoimmune disease. Cranial MRI abnormalities were
Fig. 1 A diagram illustrating the distribution of all reported ACP5
pathogenic variants. Below the gene diagram data are shown from this
study with number of alleles per variant observed in parentheses; in
addition pathogenic variants not identified in this study, but previously
reported by Lausch et al. [8] and Girschick et al. [17] are depicted above
the gene diagram
Fig. 2 A skeletal survey in a
patient with biallelic ACP5
mutations. Imaging in Patient
14 at age seven years identified
platyspondyly and lacunar lesions
localized to the posterior third of
the vertebral bodies (a);
radiolucent lesions extending
from the growth plate into the
metaphysis of the long bones of
the distal radius and ulna (b),
proximal fibula and tibia (c) and
the distal femora (d)
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detected in 8 of 16 patients assessed with features including
leukodystrophy (Table 2), and angiography in Patient 1 dem-
onstrated an intracranial aneurysm.
Neurological manifestations may evolve over time.
Patient 5 for example, was diagnosed at age 14 years
due to short stature, Raynaud’s phenomenon and a
positive family history [7]. At 19 years of age she devel-
oped lower limb pyramidal signs, which coincided with
the detection of anti-nuclear antibodies for the first time,
and a 10-fold increase in serum ISG levels compared to
five years previously. CT revealed bilateral calcifications
in the basal gangla and thalami.
Table 2 Key skeletal and neurological features of ACP5 mutation positive patients
Patient1 Last recorded height as
SD below the mean (age
at assessment)










2 5.5 (12) Yes Yes No No Yes Yes (Mild)
3 2.5 (12) No Yes NA NA No No
4 4.3 (16) Yes Yes Yes No Yes No




6 5 (13) Yes Yes Yes Ischaemic lateral
ventricle lesions
Yes Yes (Mod.)




8 4 (18) Yes Yes NA NA No No
9 6.5 (18) Yes No Yes No No No
10 3 (13) Yes Yes NA No Yes No
11 2 (12) Yes Yes No Ventricular
dilatation
Yes Yes (Severe)










13 0 (0.5) Yes Yes No NA No No
14 2.5 (10) Yes Yes NA No No No
15 6 (12) Yes Yes NA NA No No
16 4 (12) Yes Yes NA NA No No
17 3 (10) Yes Yes NA No No No
18 3.5 (36) Yes Yes No NA Yes No






20 NA NA NA NA NA NA NA





22 5.5 (35) Yes Yes Yes NA Yes Yes (Mod.)
23 2 (12) Yes Yes NA No No No
24 3 (7) Yes Yes NA No Yes No
25 3.5 (10) Yes Yes NA NA No No
26 5 (15) Yes Yes NA NA No No
Total 0–6.5 24/25 (1 NA) 24/25 (1 NA) 9/14 (12 NA) 8/16 (10 NA) 11/25 (1 NA) 7/25 (1 NA)
Further cases [8, 17] 1.8–4.2 15/15 14/15 6/8 (7 NA) 2/3 (13 NA) 4/14 (1 NA) 4/14 (1 NA)
NA Not assessed/reported, Mod moderate developmental delay
1 Patients 1 to 10 have previously been described [3, 4, 6, 7, 16] and additional data are added where available
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Immune Manifestations
Immune dysfunction was the most frequent presenting com-
plaint in our cohort, and deterioration was observed over-time.
Autoimmune Manifestations
At least one autoimmune diagnosis was present in 22 patients
(85 %), with many exhibiting more than three (Table 3). The
most commonwas AITP in a total of 12 patients (46%), seven
of whom had SLE. AITP was lethal in one patient in infancy,
and the associated morbidity in other cases was significant,
with cerebral haemorrhage in two patients. In many cases,
AITP necessitated intensive treatment with corticosteroids,
intravenous immunoglobulins, rituximab and/or splenectomy.
Seven patients with renal manifestations fulfilled ACR diag-
nostic criteria for SLE [14], whilst the other three were under
follow up for proteinuria and did not fulfil criteria. In total nine
(36 %) patients fulfilled SLE diagnostic criteria. Recurrent
fevers of unknown origin were reported in several patients.
Skin manifestations were noted, with severe eczema in four
patients. Two patients had vasculitis; in Patient 1
sclerodermatous/acrocyanotic changes were evident in the
hands and feet with oedema and sludging on capillaroscopy.
Ultimately digital auto-amputation occurred, secondary to
vasculitis. Skin biopsy in Patient 4 showed a perivascular
polymorphonuclear infiltrate without evidence of deposition
of complement or immunoglobulin, consistent with a non-
specific leukocytoclastic vasculitis [3]. Two patients had
Raynaud’s phenomenon and in one (Patient 5) capillaroscopy
demonstrated the disappearance of parallel loops of some di-
lated capillaries with slow blood flow, which was not consid-
ered reminiscent of sclerodermatous disease [15]. Additional
autoimmune phenotypes were reported, including in two pa-
tients: Sjögren’s syndrome and livedo reticularis; and in a
single patient: post-operative macrophage activation syn-
drome, pancreatitis, scleroderma and polymyositis, coeliac
disease, endocarditis and vitiligo. Disease progression was
frequently observed; Patient 4, for example, developed renal
lupus at age 15 years thus fulfilling the diagnostic criteria for
SLE, and Patient 1 developed eight autoimmune diagnoses
over a 27 year period.
Serologically, 21 of 22 patients had at least one episode of
positive antinuclear antibodies, and 15 of 21 positive anti-
dsDNA antibodies. Positive antiplatelet, anti-phospholipid,
antigliadin, antineutrophil, anti-thyroglobulin and anti
ADAMTS XII antibodies were also detected. Two autoanti-
bodies positive patients did not have clinical evidence of au-
toimmune disease.
We previously reported an association between biallelic
ACP5 mutations and elevated levels of serum IFNα and an
upregulation of ISGs in whole blood [7]. In this cohort, all ten
patients in whom serum IFNα activity levels were measured
demonstrated elevated levels, and on serial assessment, levels
were persistently high. An absence of CSF IFNα activity was
observed in Patient 1, despite neurological manifestations [3].
ISGs were measured in 11 patients, and in nine the interferon
score was significantly higher than age and sex matched con-
trols and remained elevated on repeat measurement (Table 3
and Fig. 4). In Patient 5, the initial ISG assessment undertaken
at age 14 years was marginally raised, however, a 10-fold
increase was observed five years later, in association with
neurological deterioration. Two patients, Patient 21 and
Patient 22, did not demonstrate an interferon signature.
Patient 22 did not manifest any clinical autoimmune dis-
ease to age 35 years, when ISGs were within normal range
(autoantibodies were not assessed). Features of SPENCD had
been present since adolescence, with typical skeletal findings,
spasticity, moderate intellectual disability and basal ganglia
calcification [4].
Patient 21 had a history of skeletal, neurological and im-
mune disease. He presented at one month of age with sponta-
neous bleeding and splenomegaly secondary to AITP. In the
first year of life he suffered recurrent respiratory infections,
but these resolved. He developed nephrotic syndrome at two
years of age and, following the identification of class V lupus
nephritis at four years of age, was treated with cyclosporine A
for three years with partial remission. A subsequent relapse
was managed with oral prednisone and cyclosporine A, but
was then discontinued by the family. At nine years of age he
Fig. 3 A cranial CT in a patient with biallelic ACP5 mutations. Imaging
in Patient 21 at nine years of age demonstrated intracranial calcification of
the white and grey matter junction and bilateral blush and spots in the
head of the caudate, putamen and globus pallidus and deep gyral matter
on the right and left
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developed right sigmoidal sinus thrombosis and severe hyper-
tension, renal failure with class V lupus nephritis, serositis,
(pleuritic and pericardial effusions), and dilated cardiomyop-
athy (ejection faction 34 %), with no sign of systemic infec-
tion. He had positive antinuclear and anti-dsDNA antibodies
(1:640), low C3, C4 and thrombocytopenia. Two doses of
intravenous methylprednisolone (2 mg/kg/day) and eight ses-
sions of plasmapheresis were administered, followed by oral
prednisone (2 mg/kg/day) for four weeks, which was then
tapered (0.5 mg/kg/day) and given with mycophenolate
mophetil (600 mg/m2/bd) and a dose of rituximab (375 mg/
m2). Two months later he was switched to maintenance im-
munotherapy of prednisone (0.5 mg/kg/day) and mycopheno-
late mophetil (600 mg/m2/bd). This was continued for
12 months, and twice during this period (separated by several
months) the ISG profile was assessed and an interferon signa-
ture was not detected. Follow-up during this time revealed
significantly improved autoimmune disease with non-
nephrotic proteinuria, low positive ANA titres and anti-
dsDNA antibodies (1:80), with normal C3, C4 and white cell
counts.
Manifestation of Immunodeficiency
Recurrent bacterial and viral infections were reported in five
patients, raising the suggestion that immunodeficiency is a
part of ACP5-associated disease (Table 4). Infections included
recurrent pneumonia, disseminated herpes zoster, and skin
and dental abscesses. Interpretation of immunological testing
undertaken in the cohort was difficult, in terms of differenti-
ating disease-related immunodeficiency from immune defects
resulting from immunosuppressive therapy. Low lymphocyte
count and/or hypogammaglobulinemia was evidenced in three
patients who did not receive immunuppressive drugs and in
nine treated patients (Table 4). Where lymphocyte subsets
were available, the low counts consisted of low T, B and NK
cell counts in two cases (one not treated and one treated), low
T and B cell counts in one treated case, low B and NK cell
counts in one treated case, low T and NK cell counts in one
treated case and low Tcell counts in five cases (two not treated
and three treated). Of note, Patient 6 demonstrated a persistent
hypogammaglobulinemia following rituximab treatment for
AITP, whilst prior to treatment he had normal serum
immunoglobulins.
Causes of Death and Severe Disability
Two patients died in our cohort, Patient 1 at age 30 years,
following a gastrointestinal bleed and heart failure with severe
arterial hypertension and Patient 20 before one year of age
secondary to AITP. Disease morbidity was marked, with nine
patients manifesting three or more different autoimmune di-
agnoses, which frequently required immunosuppressive ther-
apy (Table 4), or in the case of AITP splenectomy. Mental
retardation was typically of mild to moderate severity, but in
Patient 11 this was categorized as severe. Whilst stature was
variable, when 6.5 SD below the mean at 18 years this likely
impeded activities of daily living.
Discussion
This review describes the largest cohort of patients with con-
firmed biallelic ACP5 mutations yet reported. Our findings
highlight the marked clinical variability of the associated phe-
notype, ranging from infantile death secondary to AITP, to
isolated skeletal dysplasia in an adult woman. Lausch et al.
[8]. also noted variability, reporting both a 64 year old affected
male and childhood mortality. The age at which features first
became manifest ranged from birth to 15 years, similar to the
ten month to 16-year range reported by previously [8].
Clinical diversity was observed both within and between fam-
ilies, and means that patients may present to different medical
specialists, increasing possible diagnostic delay. Disease pro-
gression was observed frequently, indicating the need for con-
tinued follow up. As all ACP5 mutations assessed to date
appear functionally null, with an absence of TRAP expression
in the blood [7], additional unidentified modifying genetic
and/or environmental factors may play a role in the inter-
Fig. 4 Expression of interferon-stimulated genes in SPENCD patients
compared to controls. The median fold change for six ISGs (IFI27,
RSAD2, IFI44L, ISG15, IFIT1, SIGLEC1) as normalised to 18S/
HPRT1 is calculated to derive an interferon score. The mean interferon
score of the controls plus two standard deviations above the mean (+ 2
SD) is considered as positive (red). Overall, the score in SPENCD
patients was significantly higher than age and sex matched controls (**
p < 0.0001)
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and intra-familial variation of disease manifestations. At pres-
ent, no specific genotype-phenotype correlation is evident.
Skeletal radiological findings were a consistent feature,
thus serving as a key diagnostic handle. As was observed by
Lausch et al. [8] who identified skeletal changes in all 14
patients they reported (Table 2). However, variability was ob-
served, with subtle manifestations in some cases, and two
patients demonstrating onlymetaphyseal or vertebral changes.
A mild skeletal phenotype, with only ‘discrete metaphyseal
changes’ at the wrist was also reported byGirschick et al. [17].
In keeping with this radiological diversity, a height within the
normal range, particularly at a young age, does not exclude the
diagnosis. We note an increased bone mineral density in three
of five patients measured, which is perhaps analogous to the
ostepetrosis observed in the ACP5 knock-out mouse [18].
Over half of the cohort demonstrated features of neurolog-
ical disease, the commonest being spasticity (44 %), with on-
set as early as age two years. It is noteworthy that SPENCD/
SPENCDI demonstrates phenotypic overlap with the neuro-
inflammatory interferonopathy AGS and patients with ISG15
mutations, the hallmarks of which are intracranial calcification
and neurological dysfunction [11, 12]. Furthermore, an elevat-
ed IFNα in both the serum and CSF has been reported in a
nine year old with confirmed biallelic ACP5 mutations [17].
Thus, whilst the etiology of the neurological disease is un-
clear, we consider it likely to be secondary to abnormal im-
mune activation.
The prevalence of autoimmune disease in the cohort was
high, with 92 % of patients demonstrating clinical or serolog-
ical features of autoimmunity. The onset of autoimmune pa-
thology was early, with cytopenia before a year of age in three
patients, and with many patients developed three or more au-
toimmune diagnoses during childhood, demonstrating the
need for careful monitoring. Cytopenia was the commonest
manifestation (AITP in 46 %) and paediatric SLE was also
frequent (36 %). We propose that in cases of severe autoim-
mune disease, particularly in a consanguineous family and/or
in association with a short stature, SPENCD/SPENCDI
should be considered as a potential diagnosis.
Whilst autoimmune disease was not observed in all
cases of ACP5 related disease, a diverse range of organ-
specific and systemic autoimmune conditions were detect-
ed. Part of the explanation for these disorders likely re-
lates to elevated type I interferon levels, which are asso-
ciated autoimmune disease [19]. Elevated levels of serum
IFNα and/or ISGs were recorded in the majority of pa-
tients tested (Table 3 and Fig. 4). We hypothesize that
type I interferon is elevated in TRAP deficiency because
TRAP may be a negative regulator of IFNα, perhaps via
its action upon osteopontin. Osteopontin, a highly phos-
phorylated glycoprotein, forms a signalsome with TLR9
and MyD88 in mice and appears integral to IFNα produc-
tion in murine plasmacytoid dendritic cells [20].
The absence of ISGs in Patient 21 during maintenance
immunosuppressive therapy suggests that the treatment was
effective at both a symptomatic and a biochemical level. The
identification of an effective therapy, even if multimodal, is
important, as SPENCD related autoimmune disease may be
fatal. The normal ISG value during treatment also suggests
that the assay might be used to evaluate targeted therapies.
The observation of an absence of an interferon signature in
a patient without clinical autoimmune disease is of interest,
and an assessment of similar cases (e.g. those in Table 5) is
needed to determine whether this is a recurrent phenomenon.
As we have observed elevation of ISG expression in associa-
tion with disease progression (Patient 5), we recommend a
low threshold for the investigation of immune symptoms in
all SPENCD patients. In addition, whilst an ISG signature is
not universal in SPENCD it remains a useful screening tool
when considering the diagnosis, and may serve as a biomarker
of disease progression and future treatments.
We also note a history of recurrent bacterial and/or viral
infections in five patients, in some with associated reduced
lymphocyte counts (Table 4). Additional cases of SPENCD
with immunodeficiency may include some of the patients de-
scribed by Roifman andMelamed [6], who manifested immu-
nodeficiency, autoimmunity and spondylometaphyseal dys-
plasia. One patient in the Roifman and Melamed [6] series
had a skeletal diagnosis of SPENCD on X-ray [2] and was
found to have a homozygous ACP5 mutation (Patient 8 de-
scribed here). Patient 8 had a younger brother with
metaphyseal sclerosis, a history of recurrent infections and
AITP, he died of encephalitis at age three years [6]; molecular
testing in this case and the other reported cases [6] has not
been reported. The case reported by Girschick et al. [17]
supports the association of concurrent autoimmunity and
immunodeficiency with both autoantibodies and low
CD4+, B and NK cell counts noted. The finding of recur-
rent infection in SPENCD is of interest given the suscep-
tibility to Staphylococcus aureus infection noted in the
ACP5 knock-out mouse [27]. Whilst additional data are
needed, we would recommend in the interim that patients
with biallelic ACP5 mutations should be monitored for an
infectious susceptibility and should undergo lymphocyte
phenotyping and serum immunoglobulin values prior to
immunosuppressive therapy.
The identification of biallelic ACP5 mutations in two pa-
tients without immune dysfunction is interesting; specifically,
a p.Gly109Arg homozygous mutation in Patient 18 and 22.
These unrelated patients were diagnosed in childhood (Patient
2 and 4 [4]), along with their similarly affected siblings
(Patient 1 and 5 [4], Table 5). All four individuals were
reviewed in their 30’s, and an absence of clinical autoimmune
disease was observed. Mutation testing has not been under-
taken in either sibling [4]. According to the OMIM classifica-
tion, these patients satisfy SPENCD, rather than SPENCDI
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criteria. However, our data suggest that this separation is
inappropriate, since we observed this same mutation, in
the compound heterozygote state, in two individuals, both
of whom had skeletal and autoimmune manifestations and
one neurological sequelae (Patient 22 and 23), and this
mutation was reported previously in four patients (two
in the homozygous state) who demonstrated variable skel-
etal , neurological and autoimmune features [8].
Furthermore, Lausch et al., [8] described a 10 year old
patient with a p.Gly215Arg homozygous ACP5 mutation
in whom the only extra-skeletal feature was of intracranial
calcification, i.e. a patient with ‘SPENCD’, whilst, we and
Lausch et al., [8] observed the same mutation in three
unrelated patients, from two families, all of whom had
autoimmune disease.
The suggestion that SPENCD and SPENCDI appear
to be a continuum has implications for our understand-
ing of the disease spectrum and thus patient manage-
ment. A review of the literature since 1976 identified
33 cases (beyond those with ACP5 mutations [2, 7, 8]
or those reported by Roifman and Melamed [6]) with
skeletal features consistent with a diagnosis of
SPENCD. Nine of the 33 cases also manifested a neu-
rological phenotype, and three were diagnosed with SLE
(see Table 5). Of the 33 cases, from 25 families, there
were seven sibling-pairs and ten consanguineous parental
Table 5 Literature summary of cases of SPENCD in whom genetic testing has not been undertaken to our knowledge















Schorr et al. [1] Pt. 1 Male Yes (sibling of Pt. 2 [1]) Yes Yes No NR NR
Schorr et al. [1] Pt. 2 Male Yes (sibling of Pt. 1 [1]) Yes Yes No NR NR
Gustavson et al. [21] Pt. 1 Female No (sibling of Pt. 2 [21]) Yes Yes (−7.5SD at 16 years) No NR NR
Gustavson et al. [21] Pt. 2 Male No (sibling of Pt. 1 [21]) Yes Yes (−6.5SD at 13 years) No NR NR
Spranger et al. [22] Pt. 1 Male No Possibly1 Yes No NR NR
Spranger et al. [22] Pt. 2 Male NR Possibly2 Yes Dev. delay NR NR
Spranger et al. [22] Pt. 3 Male No Possibly3 Yes Dev. delay NR NR
Sauvegrain et al. [23] Pt. 1 Female No Yes Yes No NR NR
Sauvegrain et al. [23] Pt. 5 Male Yes Yes Yes Dev. delay NR NR
Chagnon et al. [24] Male No Yes Yes Spasticity NR NR
Azouz [25] Male No Yes Yes No NR NR
Ziv et al. [31] Pt. 1 Male No (sibling of Pt. 2 [31]) Yes Yes NR NR NR
Ziv et al. [31] Pt. 2 Female No (sibling of Pt. 1 [31]) Yes Yes NR NR NR
Menger et al. [30] Pt. 1 Male Yes (sibling of Pt. 2 [30]) Yes Yes (−6SD at 12 years) Dev. delay NR NR
Menger et al. [30] Pt. 2 Male Yes (sibling of Pt. 1 [30]) Yes Yes (−6SD at 6 years) Dev. delay NR NR
Menger et al. [30] Pt. 3 Male Yes (distant relative of Pt. 1 and 2 [30]) Yes Yes (−1.5SD at 12 years) No NR NR
Menger et al. [30] Pt. 4 Male Yes Yes Yes (−2SD at 6 years) Dev. delay & spasticity NR NR
Frydman et al. [4] Pt. 1 Male Yes (sibling of Pt. 18 in present cohort) Yes Yes (−3.5SD at 8 years) No No No
Frydman et al. [4] Pt. 3 Male Yes Yes NR NR NR NR
Frydman et al. [4] Pt. 5 Male Yes (sibling of Pt. 22 in present cohort) Yes Yes (−4.4SD at 8 years) Dev. delay & spasticity Yes No
Frydman et al. [4] Pt. 6 Male No Yes Yes (−5.4SD at 8 years) No Yes NR
Robinson et al. [28] Pt. 1 Male No (grandson of Pt. 2 [28]) Yes Yes (−3SD at 19 years) No NR NR
Robinson et al. [28] Pt. 2 Male NR (paternal grandfather of Pt. 1 [28]) Yes Yes (−5.5SD at 86 years) NR NR NR
Passwell et al. [32] Pt. 1 Male Yes (siblingwith skeletal phenotype, data limited) Yes Yes NR Yes SLE
Passwell et al. [32] Pt. 2 Female Yes (siblingwith skeletal phenotype, data limited) Yes Yes NR NR SLE
Passwell et al. [30] Pt. 3 Female Yes Yes Yes NR NR SLE
Uhlmann et al. [26] Pt. 1 Male No Yes Yes (−4SD at 5 years) No NR NR
Uhlmann et al. [26] Pt. 2 Male No Yes Yes NR NR NR
Tuysuz et al. [5] Pt. 1 Male No (sibling of Pt. 2 [5]) Yes Yes (−4.5SD at 9 years) No No NR
Tuysuz et al. [5] Pt. 2 Female No (sibling of Pt. 1 [5]) Yes Yes (−1.5SD at 21 years)4 No No NR
Tuysuz et al. [5] Pt. 3 Male NR Yes Yes (−4.5SD at 7 years) Dev. delay Yes NR
Bhargava et al. [29] Pt. 1 Male No (son of Pt. 2 [29]) Yes Yes (−2.5SD at 13 years) No NR NR
Bhargava et al. [29] Pt. 2 Female No (mother of Pt. 1 [29]) Yes Yes (−2.5SD at 42 years) No NR NR
Pt Patient number from original publication, Dev Delay developmental delay, NR not recorded
1 Enchondromatosis with irregular vertebral lesionss
2 Enchondromatosis with irregular vertebral lesions
3 Enchondromatosis with mild platyspondyly
4 Two years of growth hormone therapy at 12 years
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relationships, in keeping with autosomal recessive inheritance
in at 29 cases. Biallelic ACP5 mutations may be present in
these 29 cases, although genetic testing is required and genetic
heterogeneity cannot be excluded. Four further cases demon-
strate possible autosomal dominant transmission [28, 29] and
different genes may explain the aetiology in these cases.
However, the possibility of a causative heterozygous ACP5
mutation, due to haploinsufficiency, also requires consider-
ation. Most parents heterozygous for an ACP5 mutation in
our cohort appear healthy; however, two parents had short
stature, two had a history of neuropsychiatric illness, and
one psoriasis. Before conclusions can be made, genetic testing
is needed in these cases, and further assessment is required of
heterozygote ACP5 carriers.
Twelve of the 25 families reported in Table 5 are
Jewish families of Iraqi origin [1, 4, 28, 30–32].
Patient 18 and Patient 22 are both from Israel and both
harbor the same homozygous point mutation, and this
same variant was previously reported in a case of
Jewish ancestry [8]. This suggests both an increased
prevalence of SPENCD in Israel, as noted previously
[28], and raises the possibility of a common founder
mutation.
Conclusions
Biallelic ACP5 mutations are primarily associated with
skeletal, neurological and immune features, which can
be highly variable in their manifestation and severity.
Our data show that this diversity may include an absence
of autoimmune disease, and indicate that SPENCD and
SPENCDI are a continuum of the same condition. The
majority of patients demonstrate elevated expression of
ISGs, which therefore represents a useful diagnostic tool.
SPENCD is a rare condition, but may be associated with
significant childhood morbidity and mortality. Thus, there
is a need for improved understanding of the underlying
disease mechanism to facilitate the development of
targeted therapies. In the interim, multimodal immunosup-
pression may be of benefit in certain cases.
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